Osteoporosis Drugs Market Competition Analysis 2025: How Players Are Shaping Growth
Osteoporosis Drugs Global Market Report 2025
The Business Research Company's Osteoporosis Drugs Global Market Report 2025 – Market Size, Trends, And Global Forecast 2025-2034
LONDON, GREATER LONDON, UNITED KINGDOM, December 18, 2025 /EINPresswire.com/ -- "The Osteoporosis Drugs market is dominated by a mix of global pharmaceutical leaders and regional innovators. Companies are focusing on advanced drug formulations, hospital and pharmacy integration, patient adherence programs, and targeted therapeutics to strengthen market presence and improve treatment outcomes. Understanding the competitive landscape is key for stakeholders seeking growth opportunities, strategic partnership.
Which Market Player Is Leading the Osteoporosis Drugs Market?
According to our research, Amgen Inc. led global sales in 2023 with a 9% market share. The Human Therapeutics division of the company is completely involved in osteoporosis drugs market, provides the EVENITY (romosozumab) and other solutions. evenity is a bone-building therapy designed to enhance bone density and reduce fracture risks. Additionally, the division provides Prolia (denosumab), a widely used treatment for osteoporosis in individuals at high risk of fractures. These products reflect Amgen's commitment to advancing bone health through innovative therapies.
How Concentrated Is the Osteoporosis Drugs Market?
The market is concentrated, with the top 10 players accounting for 40% of total market revenue in 2023. This concentration reflects the dominance of well-established pharmaceutical companies with strong clinical portfolios, extensive R&D capabilities, and global distribution networks. Leading manufacturers such as Amgen, Eli Lilly, Pfizer, and Eisai maintain significant market influence through innovative therapies, biologics development, and continuous advancements in osteoporosis treatment. As demand for effective fracture prevention and long-term bone-strengthening treatments increases, these key companies are expected to reinforce their leadership through product innovation, strategic collaborations, and expansion into emerging markets.
Leading companies include:
o Amgen Inc. (9%)
o Eli Lilly and Company (4%)
o Pfizer Inc. (4%)
o Eisai Co., Ltd. (4%)
o Apotex Inc. (4%)
o AbbVie Inc. (3%)
o Novartis AG (3%)
o Sanofi S.A. (3%)
o GSK plc (3%)
o Daiichi Sankyo Company, Limited (3%)
Request a free sample of the Osteoporosis Drugs Market report:
https://www.thebusinessresearchcompany.com/sample_request?id=9102&type=smp
Which Companies Are Leading Across Different Regions?
North America: Sandoz Inc., Apotex Corp., AbbVie Inc., Amgen Inc., Mylan Pharmaceuticals Inc., Merck & Co., Inc., Novartis AG, Eli Lilly and Company, Pfizer Inc., Novartis Pharmaceuticals Corporation, Radius Health, Inc. and Horizon Therapeutics plc are leading companies in this region.
Asia Pacific: Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Merck Sharp & Dohme Corp., Roche Holding AG, Transcenta Holding Ltd., Shanghai Henlius Biotech, Enzene Biosciences Ltd., Daiichi Sankyo Co., Ltd., Eden Biologics, Zydus Lifesciences Ltd., Mabwell (Shanghai) Bioscience Co., Ltd., Eisai Co., Ltd., Strides Pharma Science Ltd., Asahi Kasei Corporation, Pharmac, Axial Therapeutics, Acrux Limited, Cynata Therapeutics Ltd., Kyowa Kirin Co., Ltd., Cadila Pharmaceuticals Ltd., Luye Pharma Group Ltd., Pharmed Limited, Chugai Pharmaceutical Co., Ltd. and Towa Pharmaceutical Co., Ltd. are leading companies in this region.
Western Europe: Roche Holding AG, Eli Lilly and Company, Novartis AG, GlaxoSmithKline plc, UCB S.A., Sandoz AG, Enzene Biosciences Limited, Fresenius Kabi AG, Gedeon Richter Plc, Alvotech hf., Mabxience Holding S.L., Theramex HQ Limited, Sanofi S.A., Novo Nordisk A/S, Bristol Myers Squibb Company, Ferring Pharmaceuticals, Laboratoires Servier SAS, Grünenthal GmbH, OsteoSys Co., Ltd., Medimaps Group SA and Pharmanovia AB are leading companies in this region.
Eastern Europe: Glenmark Pharmaceuticals Ltd., Dr. Max Group, Teva Pharmaceutical Industries Ltd., Polpharma S.A., Celon Pharma S.A., Hasco-Lek S.A. and Biofarma S.A. are leading companies in this region.
South America: Amgen Inc., Eli Lilly and Company, Merck & Co., Inc. and Pfizer Inc. are leading companies in this region.
What Are the Major Competitive Trends in the Market?
• Innovative approaches and regulatory approvals to enhance treatment outcomes
• Example: Teva Pharmaceuticals Inc. Forteo (teriparatide injection) (November 2024) recommended for postmenopausal women with osteoporosis at high fracture risk who are unable to use alternative treatments.
• These innovations support men with primary or hypogonadal osteoporosis, as well as individuals with glucocorticoid-induced osteoporosis, particularly those at high fracture risk who cannot use alternative therapies.
Which Strategies Are Companies Adopting to Stay Ahead?
• Launching innovative drug formulations and therapies to strengthen market position
• Enhancing research & development funding and strategic collaborations to accelerate pipeline growth
• Focusing on patient adherence programs and hospital/pharmacy partnerships to improve treatment outcomes
• Leveraging digital health platforms and telemedicine solutions for patient monitoring and scalable care delivery for scalable risk management
Access the detailed Osteoporosis Drugs Market report here:
https://www.thebusinessresearchcompany.com/report/osteoporosis-drugs-global-market-report
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. We have published over 17,500 reports across 27 industries and 60+ geographies. Our research is powered by 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.
We provide continuous and custom research services, offering a range of specialized packages tailored to your needs, including Market Entry Research Package, Competitor Tracking Package, Supplier & Distributor Package and much more.
Disclaimer: Please note that the findings, conclusions and recommendations that TBRC Business Research Pvt Ltd delivers are based on information gathered in good faith from both primary and secondary sources, whose accuracy we are not always in a position to guarantee. As such TBRC Business Research Pvt Ltd can accept no liability whatever for actions taken based on any information that may subsequently prove to be incorrect. Analysis and findings included in TBRC reports and presentations are our estimates, opinions and are not intended as statements of fact or investment guidance.
Contact Us:
The Business Research Company
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company"
Oliver Guirdham
The Business Research Company
+44 7882 955267
info@tbrc.info
Visit us on social media:
LinkedIn
Facebook
X
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
